FY2029 Earnings Estimate for EVAX Issued By HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for Evaxion Biotech A/S in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of $0.11 for the year. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share.

Separately, Lake Street Capital reduced their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday.

Evaxion Biotech A/S Stock Down 8.6 %

EVAX stock opened at $2.99 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The business has a 50 day moving average of $4.69 and a 200 day moving average of $10.53. Evaxion Biotech A/S has a twelve month low of $2.22 and a twelve month high of $23.70. The firm has a market cap of $3.50 million, a PE ratio of -2.06 and a beta of -0.28.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.